skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Effect of protease inhibitors (indinavir and ritonavir) on the pharmacokinetics of gliclazide in rabbits

Original Research

(2317) Views  (454) Full article downloads

Authors: Kilari Eswar Kumar, Shaik Mastan

Published Date January 2011 Volume 2011:1 Pages 1 - 9
DOI: http://dx.doi.org/10.2147/RRED.S16496

Kilari Eswar Kumar1, Shaik Mastan2,3
1Pharmacology Division, University College of Pharmaceutical Sciences, Andhra University, Visakhapatnam, Andhra Pradesh, India; 2Research and Development Cell, Jawaharlal Nehru Technological University, Hyderabad, Andhra Pradesh, India; 3Cytel Statistical Software and Services Pvt Ltd, Pune, Maharashtra, India

Abstract: The objective of this study was to investigate the effect of protease inhibitors (indinavir and ritonavir) on the pharmacokinetics of gliclazide in rabbits and to evaluate the mechanism of interaction of the combination. Studies in rabbits were conducted with oral doses of gliclazide, selected protease inhibitor, and their combination with a 1-week washout period between each treatment (single dose followed by multiple dose treatment). Blood samples were collected at regular time intervals by marginal ear vein puncture and serum gliclazide levels were analyzed by high-pressure liquid chromatography. Pharmacokinetic analysis was performed by noncompartmental analysis using WinNonlin Software. In combination, ritonavir significantly increased serum gliclazide levels and altered the pharmacokinetic parameters of gliclazide in rabbits while indinavir had no significant effect. The percentage increase of serum gliclazide level was 22.34% and 27.78% following single-dose and multiple-dose treatment of ritonavir, respectively. The interaction of ritonavir with gliclazide is pharmacokinetic at a metabolic level (by CYP3A4 inhibition) in normal rabbits, while the interaction of indinavir with gliclazide is pharmacodynamic, which needs dose adjustment, and care should be taken when these combinations are prescribed for their clinical benefit in diabetic patients.

Keywords: gliclazide, indinavir, ritonavir, diabetes, HIV infection, pharmacokinetics




 

Other articles by Mr SK Mastan



Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Effect of antiretroviral drugs on the pharmacodynamics of gliclazide with respect to glucose–insulin homeostasis in animal models
Retinal nerve fiber layer thickness in recovered and persistent amblyopia
The basic regulatory considerations and prospects for conducting bioavailability/bioequivalence (BA/BE) studies – an overview
Predicting response to incretin-based therapy
Solid self-nanoemulsifying cyclosporin A pellets prepared by fluid-bed coating: preparation, characterization and in vitro redispersibility
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Evaluation of analgesic efficacy of bromfenac sodium ophthalmic solution 0.09% versus ketorolac tromethamine ophthalmic solution 0.5% following LASEK or Epi-LASIK
Folates for reduction of risk of neural tube defects: using oral contraceptives as a source of folate
Treatment of diabetic vasculopathy: an overview